.png)
.png)
Director of Infectious Disease Research
Beaumont Health
Disclosure(s): Astra Zeneca: Grant/Research Support; ContraFect: Grant/Research Support; Crestone: Grant/Research Support; Diasorin Molecular LLC: Grant/Research Support; Epigenomics Inc: Grant/Research Support; EUROIMMUN US: Grant/Research Support; Finch Theraputics: Grant/Research Support; Genentech USA Inc: Grant/Research Support; Janssen Research and Development LLC: Grant/Research Support; Kinevant Sciences GmBH: Grant/Research Support; Leonard-Meron Biosciences: Grant/Research Support; Lysovant: Grant/Research Support; Merck: Grant/Research Support; OpGen: Grant/Research Support; Prenosis: Advisor/Consultant, Grant/Research Support; Qiagen: Grant/Research Support; Regeneron Pharmaceuticals: Grant/Research Support; Seres Therapeutics Inc: Grant/Research Support; Shire: Grant/Research Support; Summit Therapeutics: Grant/Research Support
Matthew Sims, M.D. Ph.D., FACP, FIDSA. Director of Infectious Diseases Research, Beaumont Health, Royal Oak, MI. Professor of Internal Medicine and Foundational Medical Studies, Oakland University William Beaumont School of Medicine, Rochester, MI
Dr. Sims received his MD and PhD from Stony Brook University with his PhD in Genetics focused on antifungal resistance. He went on to an Internal Medicine residency at Stony Brook and from there to University of Rochester for his Infectious Diseases fellowship followed by an Infectious Diseases research fellowship focused on the impact of antiretroviral resistance mutations on the replication fitness of HIV. He was recruited to start an Infectious Diseases research program for Beaumont Hospital, Royal Oak, in 2006.
Dr. Sims’ laboratory based research focuses on resistant and difficult to treat pathogens, the so-called “superbugs” as well as new diagnostics for infections. Dr. Sims runs Beaumont’s Infectious Diseases Clinical Trial Unit and has extensive clinical research experience, serving as PI on over 80 clinical trials of antibiotics and diagnostics. He has extensive collaborations outside Beaumont and is active with the Antibiotic Resistance Leadership Group (ARLG). His research has been funded by grants from foundations, the State of Michigan and the federal government and he currently has an R01 funded by the Agency for Healthcare Research and Quality to study prevention of C. difficile infection.
Since the COVID-19 pandemic hit Michigan he has focused the majority of his attention on this disease and is primary investigator on multiple trials and is the author and primary investigator for the BLAST COVID-19 study which is one of the largest studies to date looking at antibody formation in response to COVID with the goal of determining if those antibodies protect people from becoming infected with the virus.